Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Cancer Anorexia-Cachexia Syndrome (CACS) Market Grown from 2024 to 2025?
The market for cancer anorexia-cachexia syndrome (CACS) has advanced rapidly in the past years. Expected to rise from $3.51 billion in 2024 to $3.89 billion in 2025, it’s predicted to have a compound annual growth rate (CAGR) of 11.0%. The significant growth in the past was due to factors like a higher occurrence of cancer, increased awareness among healthcare professionals, improved focus on cancer patients’ quality of life, growth in clinical trials, and collaboration and partnerships within the pharmaceutical industry.
What Growth Rate Is Anticipated for the Cancer Anorexia-Cachexia Syndrome (CACS) Market in the Coming Years?
Anticipations are increasing concerning the quick expansion of the cancer anorexia-cachexia (CACS) market in the forthcoming years. It is projected to escalate to $5.84 billion by 2029, with a compound annual growth rate (CAGR) of 10.7%. This predicted surge could be credited to improvements in cancer survival rates, augmenting investments in the fields of oncology supportive care, expansion in personalized medicine, an enhanced emphasis on multimodal treatments, and a swelling healthcare infrastructure. Key trends projected during this period comprise of advancements in palliative care, the development of precision therapies, technological leaps in drug delivery systems, the incorporation of AI in the pharmaceutical developmental process, and personalized medicines.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp
Who Are the Leading Companies in the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.
What Are the Key Drivers of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
The growing incidents of cancer worldwide are set to fuel the expansion of the cancer anorexia-cachexia syndrome market. The term “cancer” constitutes a collection of illnesses defined by unregulated proliferation and metastasis of anomalous cells in the human body. Global cancer incidences are on an upswing due to reasons like aging demographics, lifestyle upheavals, environmental contact, enhanced diagnostic techniques, and heightened consciousness, supplemented by genetic tendencies and specific cancer-related infections. The cancer anorexia-cachexia syndrome (CACS) concentrates on managing the rampant weight loss and malnourishment frequently observed in cancer victims, bettering their life quality and therapy consequences. As an example, in August 2024, as per data released by Macmillan Cancer Support, a charity group based in the UK, cancer was prevalent in more than three million UK citizens, with projections estimating an increment to 3.5 million by 2025, 4 million by 2030 and 5.3 million by 2040. Therefore, the escalating cancer occurrence is enhancing the expansion of the cancer anorexia-cachexia syndrome market. Growth Of The Market Impacted By Surging Healthcare Expenditure
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp
What Are the Key Market Segments in the Cancer Anorexia-Cachexia Syndrome (CACS) Industry?
The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented –
1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration
5) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions
What Are the Latest Trends in the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Leading businesses in the cancer anorexia-cachexia syndrome market are concentrating on the creation of novel solutions, such as monoclonal antibody therapies, to boost treatment effectiveness, advance patient outcomes, and cater to unresolved clinical requirements. These therapies employ lab-manufactured antibodies that are intended to specifically target antigens found on cancer cells, thereby bolstering the immune system to identify and combat them more efficiently. For instance, Pfizer Inc., a pharmaceutical and biotechnology firm based in the US, released encouraging results from a Phase II clinical trial of ponsegromab, a monoclonal antibody that targets Growth/Differentiation Factor 15 (GDF-15), in September 2024. The positive findings from this study represent potential new treatment possibilities for those affected by this incapacitating ailment, where presently, there are limited effective therapies available. The results from the Phase 2 trial indicate substantial advancements in managing the fundamental inflammatory processes linked with muscle and weight loss in cancer patients. The aim of this treatment plan is not just to enhance physical function, but also to improve the overall life quality of patients with cancer, demonstrating a significant advancement in cancer care.
Access The Full Report Here:
What Are the Key Regional Markets in the Cancer Anorexia-Cachexia Syndrome (CACS) Industry?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125
This Report Delivers Insight On:
1. How big is the cancer anorexia-cachexia syndrome (cacs) market, and how is it changing globally?
2. Who are the major companies in the cancer anorexia-cachexia syndrome (cacs) market, and how are they performing?
3. What are the key opportunities and risks in the cancer anorexia-cachexia syndrome (cacs) market right now?
4. Which products or customer segments are growing the most in the cancer anorexia-cachexia syndrome (cacs) market?
5. What factors are helping or slowing down the growth of the cancer anorexia-cachexia syndrome (cacs) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model